B-cell lymphoma
Conditions
Interventions
Treatment group:Oral maintenance therapy with lenalidomide
Sponsors
The Second Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years and = 1x10^9/L, platelet count (PLT) >= 75x10^9/L, unless due to bone marrow invasion; 5. Biochemical indicators before enrollment must be within the following ranges: (1) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 40ml/min; 6. The LVEF value determined by echocardiography is within the normal range of the institution; 7. The researcher judges that the life expectancy is >= 3 months.
Exclusion criteria
Exclusion criteria: 1. The presence of central nervous system lymphoma. 2. Associated with uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, serious infectious diseases and other diseases. 3. Pregnant or lactating patients. 4. The presence of human immunodeficiency virus (HIV) virus infection. 5. There is a history of other malignant tumors in the past, unless the disease has been cured for 5 years or more. Except for the following tumors that have been cured: (1) Skin basal cell carcinoma, skin squamous cell carcinoma and related localized non-melanoma skin cancer; (2) Cervical carcinoma in situ.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate ;Progress Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Response;Overall Survival;Adverse Event Rate; | — |
Countries
China
Contacts
Public ContactWang Xiaobo
The Second Affiliated Hospital of Dalian Medical University
Outcome results
None listed